Balovaptan

Balovaptan
Clinical data
Other namesRG7314
ATC code
  • None
Legal status
Legal status
Identifiers
  • 8-Chloro-5-methyl-1-(4-pyridin-2-yloxycyclohexyl)-4,6-dihydro-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC22H24ClN5O
Molar mass409.92 g·mol−1
3D model (JSmol)
  • CN1CC2=NN=C([C@H]3CC[C@@H](CC3)OC3=CC=CC=N3)N2C2=C(C1)C=C(Cl)C=C2
  • InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3/t15-,18-
  • Key:GMPZPHGHNDMRKL-RZDIXWSQSA-N

Balovaptan (INNTooltip International Nonproprietary Name; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of post-traumatic stress disorder.[1]

  1. ^ "Roche - Pipeline". 2023. Retrieved 5 April 2023.